Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00653055
- Locations
- π¨π¦
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00653419
- Locations
- π¨π¦
Phoenix International Life Sciences, Inc., St-Laurent, Quebec, Canada
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fed Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00652704
- Locations
- π¨π¦
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: Megestrol acetate concentrated suspension 125 mg/mL
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00637403
- Locations
- πΊπΈ
SFBC International, Miami, Florida, United States
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Phase 3
Terminated
- Conditions
- AnorexiaCachexiaWeight Loss
- Interventions
- Drug: Megestrol acetate concentrated suspension 110 mg/mLDrug: Placebo
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00637728
- Locations
- πΊπΈ
Innovative Medical Research of South Florida, Inc, Miami, Florida, United States
πΊπΈWestern Maryland Health System, Cumberland, Maryland, United States
πΊπΈLowcountry Hematology & Oncology, PA, Mt. Pleasant, South Carolina, United States
Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
Phase 3
Terminated
- Conditions
- Weight LossAnorexiaCachexia
- Interventions
- Drug: PlaceboDrug: Megestrol acetate concentrated suspension 110 mg/mLDrug: Megestrol acetate concentrated suspension 60 mg/mL
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00637806
- Locations
- πΊπΈ
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
πΊπΈFour Seasons Hospice and Paliative Care, Flat Rock, North Carolina, United States
πΊπΈWake Forest University, High Point, North Carolina, United States